On the basis of the results presented in this study and along with the earlier pharmacology studies , it is anticipated that opicapone adjunct therapy at the dosages of 25 and 50 mg will provide an enhancement in levodopa availability that will translate into clinical benefit for Parkinson 's disease patients .